GEORGIA BOARD OF PHARMACY
Board Meeting
2 Peachtree St., NW, 36th Floor
Atlanta, GA 30303
September 18, 2013
9:30 a.m.

The following Board members were present:
Al McConnell, Chairperson
Tony Moye, Vice-Chairperson
Mike Faulk
Chris Jones
Pat McPherson *(departed @ 3:00 p.m.)*
Laird Miller
Bill Prather *(departed @ 4:03 p.m.)*
Ronnie Wallace

Staff present:
Tanja Battle, Executive Director
Rick Allen, GDNA
Janet Wray, Senior Assistant Attorney General
Brandi Howell, Licensure Analyst

Visitors:
Mark Sharer
Jimmy England
Ashley Cole
Hal Henderson
Nirmal Patel
Melvin Smith
Vincent Harville
Fran Cullen
John Holstein
Roderick Lindsay
Linda Chapman

Chairperson McConnell established that a quorum was present and called the meeting to order at 9:44 a.m.

Laird Miller made a motion and Bill Prather seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. §43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Tony Moye, Mike Faulk, Chris Jones, Pat McPherson, Laird Miller, Bill Prather and Ronnie Wallace.

Executive Session

Appearances

- M.D.S.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Hearing

An Administrative Hearing on applicant John Randall Holstein was conducted at 10:30 a.m.

Ronnie Wallace made a motion and Chris Jones seconded to enter into Executive Session for deliberation. Voting in favor of the motion were those present who included Al McConnell, Tony Moye, Mike Faulk, Chris Jones, Pat McPherson, Laird Miller, Bill Prather and Ronnie Wallace.

Chairperson McConnell declared the meeting back in Open Session.

The Review Hearing was adjourned at 1:03 p.m.

Approval of Minutes
Ronnie Wallace made a motion to approve the Public and Executive Session minutes for the August 21, 2013 full Board meeting. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Ratifications
Ronnie Wallace made a motion to ratify the list of issued licenses. Pat McPherson seconded and the Board voted unanimously in favor of the motion.

Correspondence from Wanda K. Rogers
The Board considered this correspondence and directed staff to respond to Ms. Rogers by requesting to know whether or not the request complies with Board Rule 480-10-.14 Destruction of Controlled Substance Drugs and Dangerous Drugs.

Correspondence from Sachin Kalaria, RPH021629
The Board considered this correspondence and directed staff to respond to Mr. Kalaria by stating that based on the information provided it does not appear that this procedure would be legal now; however, be advised that there are some law changes that are likely to be put in place within the next few months and to check back with the Board office.

Correspondence from William B. Alfrey, RPH016417
The Board considered this correspondence from Mr. Alfrey requesting the Board terminate his consent order. Ronnie Wallace made a motion to approve the request effective 10/01/2013. Pat McPherson seconded and the Board voted unanimously in favor of the motion.

Correspondence from Charles L. Posey, RPH010446
The Board considered this correspondence from Mr. Posey requesting the Board lift his probation. Tony Moye made a motion to approve the request. Bill Prather seconded and the Board voted unanimously in favor of the motion.

Correspondence from Sidney Welch
The Board considered this correspondence. Ronnie Wallace made a motion to table the request until next month. Pat McPherson seconded and the Board voted in favor of the motion.

Emergency Rule Hearing
Tony Moye made a motion to adopt emergency Rule 480-34-0.12-.08 Additional Synthetic Cannabinoids with the changes noted. Pat McPherson seconded and the Board voted unanimously in favor of the motion.

480-34-0.13-.08 Additional Synthetic Cannabinoids.

(a) This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, collectively known as Synthetic Cannabinoids, under Schedule I, of the Georgia Controlled Substances Act, Code Section 16-13-25 (12) as follows:

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA)
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-Fluoro-ADBICA)
This rule includes any material, compound, mixture, or preparation which contains the substances or their isomers, halogen analogues, and/or homologues.
(b) This rule is based on the following findings of the Board:
(1) that Synthetic Cannabinoids have an extremely high potential for abuse;
(2) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;
(3) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;
(4) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;
(5) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;
(6) that these compounds have no known precursor already scheduled under the Act; and
(7) that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.
(8) that this emergency rule includes any material, compound, mixture or preparation which contains the substances or isomers, halogens, analogues, and/or homologues.

Laird Miller made a motion to adopt emergency Rule 480-34-0.14-.01 Additional Synthetic Cathinone and Rule 480-34-0.13-.10 Additional Synthetic Cannibinoids. Mike Wallace seconded and the Board voted unanimously in favor of the motion.

480-34-0.15-.10 Additional Synthetic Cathinone.

(a) This rule was adopted to protect the health, safety, and welfare of the public. This rule places an additional newly identified compound, collectively known as a Synthetic Cathinone, under Schedule I, of the Georgia Controlled Substances Act, Code Section 16-13-25 (12) as follows:
N-acetyl-3,4-methylenedioxymethcathinone
(b) This rule is based on the following findings of the Board:
(1) that Synthetic Cathinones have an extremely high potential for abuse;
(2) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;
(3) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;
(4) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;
(5) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;
(6) that these compounds have no known precursor already scheduled under the Act; and
(7) that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.

480-34-0.14-.09 Additional Synthetic Cannabinoids.

(a) This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, collectively known as Synthetic Cannabinoids, under Schedule I, of the Georgia Controlled Substances Act, Code Section 16-13-25 (12) as follows:

This emergency rule includes any material, compound, mixture, or preparation which contains the substances or their isomers, halogen analogues, and/or homologues.
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA)
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-Fluoro-ADBICA)
(b) This rule is based on the following findings of the Board:
(1) that Synthetic Cannabinoids have an extremely high potential for abuse;
(2) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;
(3) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;
(4) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;
(5) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;
(6) that these compounds have no known precursor already scheduled under the Act; and
(7) that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.

A motion was made by Laird Miller, seconded by Chris Jones, and the Board voted that pursuant to O.C.G.A. Section 26-4-28(a)(9), the Board has the right to seize any drugs and devices found by the Board to constitute an imminent danger to the public health and welfare. Pursuant to O.C.G.A. Section 26-3-4(a) any duly authorized agent of the Board who finds or has probable cause to believe any drug is adulterated or misbranded as to be dangerous or fraudulent may tag the article to detain or embargo the article. If the article is unsound or unsafe, O.C.G.A. Section 26-3-4(d) authorizes the Board or its authorized agents to condemn or destroy the article. The agents of the Georgia Drugs and Narcotics Agency ("GDNA") are authorized agents of the Board. O.C.G.A. Section 26-4-29(b)(5) authorizes agents of GDNA to seize and take possession of all articles of contraband. O.C.G.A. Section 26-4-29(b)(7) provides that the GDNA shall perform such other duties as the Board may direct.

In consideration of these Code sections and the danger to the public health, safety and welfare, the Board is directing GDNA to take the lead in enforcement of Emergency Rules 480-34-0.12-.08, 480-34-0.14-.01 and 480-34-0.13-.10, and is directing that GDNA designate, on behalf of the Board, POST certified officers who are members of state and local law enforcement agencies to act as Board agents to: (1) seize drugs, compounds and/or articles identified in 2 Emergency Rules 480-34-0.12-.08, 480-34-0.14-.01 and 480-34-0.13-.10 on behalf of the Board and to maintain such seized drugs, compounds and/or articles within their evidence rooms, or (2) tag adulterated or misbranded drugs identified in Emergency Rules 480-34-0.12-.08, 480-34-0.14-.01 and 480-34-0.13-.10 to detain or embargo such drugs. Any law enforcement agencies operating on behalf in the Board in enforcing Emergency Rules 480-34-0.12-.08, 480-34-0.14-.01 and 480-34-0.13-.10 shall provide GDNA with notification of any seizure, detention or embargo. Finally, GDNA is authorized to utilize in enforcing Emergency Rules 480-34-0.12-.08, 480-34-0.14-.01 and 480-34-0.13-.10 any state agency identified in O.C.G.A. Section 26-3-18.

Miscellaneous
Tony Moye made a motion to post the following rules:

480-1-.01 Organization of the Board. Amended.

The Georgia State Board of Pharmacy consists of eight (8) members who are commissioned by the Governor. The public may obtain information from the Board, and make submissions and requests to the

Board by contacting the Executive Director of the State Board of Pharmacy at The Department of Community Health, 2 Peachtree Street, S.W., 36th Floor, Atlanta, Georgia 30303. ~~Division Director of the Professional Licensing Boards Division, located at 237 Coliseum Drive, Macon, Georgia 31217.~~

480-3-.03 Continuing Pharmacy Education.

(1) The Georgia State Board of Pharmacy has the statutory responsibility and authority for the requirement of continuing education as prerequisite for a license renewal.
(2) The purpose of continuing education for pharmacists is to maintain and enhance the professional competency of pharmacists licensed to practice in Georgia for the protection of the health, safety and welfare of the people of the State of Georgia.
(3) As a requirement for the biennial renewal of his/her license, a pharmacist must complete not less than thirty (30) hours of approved continuing education.
(4) One hour of C.E. is defined as 0.1 C.E.U. Each pharmacist in the State of Georgia must obtain 30 hours of continuing education or 3.0 C.E.U.'s per biennium for license renewal.
(a) Certificates documenting that 30 hours of approved continuing education or 3.0 C.E.U.'s must be completed and dated within the biennium.
(5) A pharmacist licensed before or during the first six (6) months of the biennium (January to June), shall be required to obtain 30 hours of C.E. A pharmacist licensed during the following twelve (12) months (June to July) shall be required to obtain 15 hours of C.E. A pharmacist licensed during the last six (6) months of the biennium shall be exempt from continuing education for that biennium only.
(6) In the event of an audit and a pharmacist fails to submit certificates, which document his/her required continuing education credits, the Board will not process his/her request to renew the license until the continuing education requirements are provided to the Board.
(a) The pharmacist may not carry over continuing education credits from one licensing period to the next.
(b) Nothing is meant to prohibit representatives from the Georgia Drugs and Narcotics Agency (GDNA) from assisting, auditing, or verifying a pharmacist's continuing education certificates as needed.
(c) Each licensed pharmacist shall maintain these certificates of attendance at continuing education meetings for a period of two (2) years from the date of the preceding renewal period.
(7) The staff of the ~~Professional Licensing Boards~~ Office of the Board of Pharmacy may audit, or otherwise select randomly, the continuing education of a percentage of licensees as determined by the Board.
(8) The Board shall accept all continuing education approved by other Boards of Pharmacy provided those Boards reciprocate this courtesy with Georgia.
(9) Approval of providers and sponsors shall be as follows:
(a) All providers and sponsors of continuing education must be approved by the Board.
(b) American Council on Pharmaceutical Education (A.C.P.E.) approved providers shall submit documentation to the Board of such approval every two (2) years and have blanket approval.
(c) All other providers shall request approval of programs as a provider on the program approval form each time a program is presented. Nothing in these rules are meant to prohibit the Board and/or GDNA from establishing a program or programs which can be granted special program approval(s) by the Board, and which may be utilized on more than one occasion or whenever such program or programs are presented by the Board or GDNA during a biennium.
(10) The following criteria for quality shall be used for the approval of providers:
(a) There shall be an administrative authority charged with the responsibility of maintaining the criteria for quality in continuing education programming for each provider.
(b) The administration shall be stable and an established procedure shall exist that insures an orderly transfer of responsibilities in the event there is a change in administration.
(c) Providers shall present a program or activity based on the needs of the target audience or the timeliness of the topic.
(d) Program objectives and rationale shall be stated.

(e) Providers shall give adequate, advanced promotional information, material about target audience, goals and objectives, program content, faculty credentials and fees.
(f) Each approved provider of continuing education in the State of Georgia shall provide a means of registration of the participants at each program and a record of attendance shall be maintained for a period of five (5) years. The provider shall also furnish to each participant, adequate documentation of his successful completion of the program.
(g) There shall be a method of program evaluation established and a statement of the evaluation process planned shall accompany each application. (The Board may supply sample forms.)
(11) Providers shall furnish each participant adequate documentation of this or her participation in the program. Information shall include:
(a) Name and license number in each state of participant;
(b) Name of provider;
(c) Name of program;
(d) Hours/C.E.U. completed;
(e) Date of completion;
(f) Authorized signature.
(12) The provider shall develop policies and procedures for the management of grievances. (This does not have to be submitted to the Board.)
(13) The facility shall be appropriate and adequately equipped to support the delivery of the program.
(14) Approval of programs shall be as follows:
(a) Acceptable forms of continuing education shall be as follows:
1. Institutes, seminars;
2. Lectures, conferences, workshops;
3. Correspondence and electronically delivered courses that are A.C.P.E. approved.
(b) The following are not acceptable as continuing educations programs: welcoming remarks, business sessions, unstructured demonstrations, degree programs, or medical continuing education programs which are not A.C.P.E. or Georgia Board approved.
(15) All continuing education providers seeking approval of the continuing education program by the Georgia Board shall submit a program approval form for each program presented. These forms should be submitted sixty (60) days in advance. The Board may exempt programs from this advance time requirement period as set forth by Board policy.

480-6-.01 Pharmacy Licenses. Amended.

(1) Application for license:
(a) Applications must be filed in duplicate with the Georgia State Board of Pharmacy located at ~~237 Coliseum Drive in Macon, Georgia 31217~~ the Department of Community Health, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303, along with the required fee.
(b) Application for the licensing of a pharmacy will be considered on the basis of the application filed and an approval letter received from the director of the Georgia Drugs and Narcotics Agency certifying the pharmacy possesses the necessary facilities and equipment for a license.
(c) The application fee shall NOT be refundable.
(2) Every pharmacy shall be under the direct charge of a registered pharmacist whose name shall appear on the license. In the event such pharmacist whose name shall appear on said license shall no longer be in charge of a pharmacy, the Board shall be notified immediately and shall be notified, at the same time, of the successor registered pharmacist.
(3) Licenses shall not be transferable. Licenses become null and void upon the sale, or change of mode of operation of the business.
(4) Licenses shall be renewed every two years and expire on June 30th of each odd year and may be renewed upon the payment of the required fee and the filing of an application for renewal. If the application for renewal is not made and the fee paid before September 1st of the odd year, the license shall lapse and shall not be renewable except by application for a new license.

Chris Jones seconded and the Board voted unanimously in favor of the motion.

A motion was made by Laird Miller, seconded by Chris Jones, and the Board voted that the formulation and adoption of these amendments do not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rule cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.
In the same motion, the Board voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A§ 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rules will impact every licensee in the same manner and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

Georgia Drug and Narcotics Agency – Rick Allen
No report.

Attorney General's Report – Janet Wray
Ms. Wray discussed pending administrative cases and attorney time for FY2013.

Executive Director's Report – Tanja Battle
No report.

Ronnie Wallace made a motion and Pat McPherson seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. §43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Tony Moye, Mike Faulk, Chris Jones, Pat McPherson, Laird Miller, Bill Prather and Ronnie Wallace.

Executive Session

Miscellaneous
Judy Gardner and Eric Lacefield discussed the results of the August examination.

Georgia Drugs and Narcotics Agency – Rick Allen
- S.D.C. and P.C.P.V.S.

Cognizant's Report – Tony Moye
- GDNA Case #A13-54
- GDNA Case #B-30833
- GDNA Case #A-30846
- GDNA Complaint #B-30792
- GDNA Case #B-30784
- GDNA Case #B-30821
- GDNA Case #B-30820
- GDNA Case #B-30789
- GDNA Case #T-13-38
- GDNA Case #B-30765
- GDNA Case #A13-56
- GDNA Case #A13-57
- GDNA Case #T13-53
- GDNA Case #T13-50

- #A-30510-80
- #A-30510-81
- #A-30510-82
- #A-30510-83
- #A-30510-84
- #A-30510-98
- #A-30510-26
- #A-30510-27
- #A-30510-31

Attorney General's Report – Janet Wray

Ms. Wray presented the following consent orders for acceptance:

- A.P.
- K.B.

Applications

- E.M.W.
- E.T.B.
- J.M.F.
- K.S.C.
- T.J.W.
- T.J.S.
- L.G.J.
- L.D.M.
- N.C.B.
- R.H.T.
- T.P.
- T.G.
- A.M.
- L.P.
- W.D.M.
- K.L.A.
- S.L.
- K.C.P.
- T.R.E.
- I.L.I.
- A.P.
- S.M.I.
- T.I.S.
- T.I.I.
- D.M.

Correspondences/Requests

- B.Z.
- K.R.G.
- J.S.G.
- C.H.M.
- K.P./S.H.C.

- M.B.G.
- PHAR140038

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Ronnie Wallace made a motion to approve all recommendations based on deliberations in Executive Session as follows:

Appearances

- M.D.S. Approve request to terminate probation.

Miscellaneous

Judy Gardner and Eric Lacefield discussed the results of the August examination.

Georgia Drugs and Narcotics Agency – Rick Allen

- S.D.C. and P.C.P.V.S. No action taken.

Cognizant's Report – Tony Moye

- GDNA Case #A13-54 Refer to the Attorney General's office for discipline
- GDNA Case #B-30833 Close with no action
- GDNA Case #A-30846 Close with no action
- GDNA Complaint #B-30792 Close with no action
- GDNA Case #B-30784 Close with no action
- GDNA Case #B-30821 Close with no action
- GDNA Case #B-30820 Close with a letter of concern
- GDNA Case #B-30789 Close with no action
- GDNA Case #T-13-38 Revoke technician registration
- GDNA Case #B-30765 Refer to the Attorney General's office for a Cease & Desist and refer case file to the Georgia Composite Medical Board
- GDNA Case #A13-56 Refer to the Attorney General's office for discipline
- GDNA Case #A13-57 Offer Inactive Status, if respondent refuses, proceed with OMPE
- GDNA Case #T13-53 Revoke technician registration
- GDNA Case #T13-50 Accept signed Voluntary Surrender
- #A-30510-80 Refer to the Attorney General's office for discipline
- #A-30510-81 Refer to the Attorney General's office for discipline
- #A-30510-82 Refer to the Attorney General's office for discipline
- #A-30510-83 Refer to the Attorney General's office for discipline
- #A-30510-84 Refer to the Attorney General's office for discipline
- #A-30510-98 Refer to the Attorney General's office for discipline
- #A-30510-26 Refer to the Attorney General's office for discipline
- #A-30510-27 Refer to the Attorney General's office for discipline
- #A-30510-31 Refer to the Attorney General's office for discipline

Attorney General's Report – Janet Wray

Ms. Wray presented the following consent orders for acceptance:

- A.P. Private Consent Order accepted
- K.B. Private Consent Order accepted

Applications

• E.M.W.	Pharmacy Technician	Table pending receipt of additional information
• E.T.B.	Pharmacy Technician	Denied registration
• J.M.F.	Pharmacy Technician	Approved for registration
• K.S.C.	Pharmacy Technician	Approved for registration
• T.J.W.	Pharmacy Technician	Approved for registration
• T.J.S.	Pharmacy Technician	Approved for registration
• L.G.J.	Pharmacy Technician	Approved for registration
• L.D.M.	Pharmacy Technician	Denied registration
• N.C.B.	Pharmacy Technician	Denied registration
• R.H.T.	Pharmacy Technician	Approved for registration
• T.P.	Pharmacy Technician	Table pending receipt of additional information
• T.G.	Pharmacy Technician	Denied registration
• A.M.	Pharmacy Technician	Approved for registration
• L.P.	Pharmacy Technician	Approved for registration
• W.D.M.	Pharmacy Technician	Approved for registration
• K.L.A.	Pharmacist Reinstatement	Schedule for an appearance with the Board
• S.L.	Pharmacist Reinstatement	Schedule for an appearance with the Board
• K.C.P.	Pharmacist Applicant	Extension request approved pending receipt of additional information
• T.R.E.	Pharmacist Reciprocity	Approved application
• I.L.I.	Wholesaler Pharmacy	Approved renewal
• A.P.	Wholesaler Pharmacy	Approved renewal and send letter of concern
• S.M.I.	Wholesaler Pharmacy	Approved renewal
• T.I.S.	Nuclear Pharmacy	Approved renewal
• T.I.I.	Retail Pharmacy	Approved renewal
• D.M.	Pharmacist Intern	Approved renewal

Correspondences/Requests

• B.Z.	Request to lift PIC limitation	Approved request
• K.R.G.	Request to terminate probation	Approved request
• J.S.G.	Letter of admonition received	No action taken
• C.H.M.	Request for clarification	Board directed staff to respond to licensee stating that he must still comply with the terms of the consent order no matter where he lives, or else license needs to be placed on inactive status.
• K.P./S.H.C.	Request to use Key Safe	Approved request
• M.B.G.	Request to terminate limitation	Approved request to terminate limitation of direct supervision only on 09/28/2013 pending receipt of additional information.
• PHAR140038	Correspondence	Board directed Laird Miller to draft a response and send to Ms. Battle send to the complainant.

Tony Moye seconded and the Board voted unanimously in favor of the motion.

Ms. Wray discussed her meeting with the Georgia Composite Medical Board regarding Rule 480-11-.02 Compounded Drug Preparations.Amended.

The next scheduled meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, October 16, 2013, at 9:30 a.m. at the Department of Community Health's office located at 2 Peachtree Street, N.W., 36th Floor, Atlanta, GA 30303.

The Board meeting adjourned at 5:01 p.m.

Minutes recorded by Brandi P. Howell, Business Operations Specialist
Minutes edited by Tanja D. Battle, Executive Director